WHO sends 70,000 Merck Ebola vaccine doses to Congo

The World Health Organization (WHO) announced on Tuesday that it will ship 70,000 doses of an Ebola vaccine candidate developed by the U.S. pharmaceutical company Merck to the Democratic Republic of the Congo (DRC) to support the country’s ongoing Ebola virus outbreak. The shipment is expected to arrive in the capital, Kinshasa, in late September and will be distributed to affected areas over the following weeks, providing immediate protection for high‑risk contacts and health‑care workers.

Since the end of 2023, the DRC has experienced its seventh wave of Ebola, with the cumulative number of confirmed cases surpassing 2,300 and deaths exceeding 1,600. The outbreak is concentrated in remote provinces in the north and east, where health‑care resources are scarce and transportation is difficult, hampering case tracing and isolation efforts. In addition to local transmission, cross‑border population movements have raised the risk of the virus spreading to neighboring countries, drawing heightened international attention to the effectiveness of containment measures.

As a specialized agency of the United Nations, WHO’s core mission is to improve global health and coordinate disease prevention, control, and resource allocation among member states. Since its founding in 1948, the organization has played a pivotal role in numerous international public‑health crises, including the deployment of vaccines and surveillance during the 2014‑2016 West Africa Ebola epidemic. Merck’s rVSV‑ZEBOV vaccine has demonstrated approximately 97 % efficacy in previous trials and field use, leading WHO to designate it as the preferred “ring‑vaccination” option. Rapid immunisation of contacts and frontline health personnel is intended to break the chain of transmission.

The DRC Ministry of Health thanked WHO for the assistance and has already launched a vaccination campaign, initially targeting hospital staff and confirmed contacts. International non‑governmental organisations such as Doctors Without Borders and the Red Cross are helping with cold‑chain logistics and community outreach, aiming to reduce vaccine hesitancy among the local population. Nonetheless, past challenges with vaccine acceptance persist; some communities remain concerned about side effects or external interference. WHO is working with local leaders to promote science‑based health education and improve uptake.

For Taiwan, which is not a formal WHO member but participates as an observer and through international cooperation, the swift deployment of the Ebola vaccine underscores the importance of global health security mechanisms and cross‑border pharmaceutical supply chains. The experience offers valuable lessons for Taiwan’s own pandemic preparedness, vaccine development, and stock‑piling strategies. Should another high‑mortality virus emerge, Taiwan could draw on WHO’s ring‑vaccination model and multi‑stakeholder coordination to strengthen protection for domestic health‑care workers and enhance community risk communication, thereby maintaining resilience in the face of global health crises.